Skip to main content

Penile Doppler Ultrasound & Cavernosometry

Penile Doppler ultrasound (PDUS) is the primary minimally invasive imaging modality for evaluating penile hemodynamics, used to differentiate arteriogenic, venogenic, and mixed vasculogenic erectile dysfunction (ED), as well as to assess Peyronie disease plaques, penile fracture, and priapism.[1][2] Dynamic infusion cavernosometry and cavernosography (DICC) is a specialist invasive assessment with important false-positive and interpretation limitations. It is not routinely required to diagnose or treat ED.[3][4]

For the broader ultrasound primer (sonourethrogram, renal US, pelvic floor US), see Ultrasound in Reconstructive Urology. For the clinical conditions evaluated by these tests, see Erectile Dysfunction and the PDE5 inhibitor, intracavernosal injection agent, and priapism management hubs.

Physiology of Erection — Basis for Hemodynamic Testing​

Normal erection involves three hemodynamic phases that produce characteristic Doppler waveform changes:[5]

  1. Arterial inflow phase — cavernosal artery dilation → increased peak systolic velocity (PSV), high diastolic flow.
  2. Tumescence phase — expanding sinusoids compress subtunical venules → progressive decrease in end-diastolic velocity (EDV).
  3. Full erection / rigid phase — complete veno-occlusion → EDV approaches zero or becomes negative (reversed diastolic flow); resistive index (RI) approaches 1.0.

Waveforms must be interpreted with the erection phase, rigidity and technical quality; an abnormal value does not uniquely identify the cause of ED.[5][6]

Penile Doppler Ultrasound (PDUS)​

Indications​

  • Selected ED with suspected vascular disease or an unclear mechanism when the result would change counseling or treatment; failure of an oral drug does not automatically require Doppler.[1][7]
  • Pre-surgical evaluation for Peyronie disease (plaque characterization, calcification, vascular integrity).[8][9]
  • Penile fracture with equivocal clinical findings.[10]
  • Priapism — differentiation of ischemic vs non-ischemic subtypes; localization of arteriovenous fistulae.[11][12]
  • Post-revascularization follow-up.[2]
  • Young men with post-traumatic ED being considered for penile revascularization.[13]

Equipment and Setup​

  • High-frequency linear transducer (7.5–15 MHz).[2][6]
  • Patient supine or in lithotomy position.
  • Gray-scale, color Doppler, and spectral (pulsed-wave) Doppler modes.
  • Private, comfortable environment to minimize anxiety-related sympathetic tone, which impairs smooth muscle relaxation and produces false-positive results.[1]

Vasoactive Agents and Dosing Protocols​

For elective vascular ED testing, adequate cavernosal smooth-muscle relaxation is essential. Do not administer an erectogenic drug to evaluate an already prolonged erection or an acute suspected fracture. Those examinations answer different questions.[1][2]

AgentDiagnostic context
AlprostadilCaverject has a US diagnostic-adjunct indication. Its label calls for an individualized dose that produces rigidity and refers to supervised titration beginning at 2.5 µg for vasculogenic/psychogenic/mixed ED; a fixed 10–20 µg starting dose is not the label regimen
Compounded combinations, such as TrimixUsed in specialist protocols; concentrations and administered doses vary. These combinations are not FDA-approved formulations
Papaverine, with or without phentolamineHistorical/off-label intracavernosal protocols; account for prolonged erection and fibrosis risks
[7][14][15]

Published protocols differ. Bassiem's 100-patient study began alprostadil at 5 µg, escalating to 10 and 20 µg when needed; it does not support starting every patient at 10 µg.[16] Flores describes a rigidity-based institutional protocol with redosing. Record dose, timing, stimulation and erection hardness; reaching a protocol's maximum dose does not prove full relaxation if rigidity remains inadequate. Report such limitations rather than assign definite vascular disease.[1]

Use the intracavernosal-agent hub for drug preparation, contraindications and treatment dosing. Diagnostic redosing requires a trained team and a detumescence/rescue plan; it is not a home-injection instruction.

Technique — Step by Step​

  1. Baseline scan — gray-scale assessment of penile anatomy (cavernosal artery diameter, normal ~0.3–0.5 mm flaccid; tunica albuginea, septum, plaques, structural abnormalities).[2][6]
  2. Intracavernosal injection (ICI) — inject vasoactive agent into the lateral aspect of one corpus cavernosum at the mid-shaft using the preparation’s specified needle (Caverject: 29–30 gauge).[14]
  3. Serial Doppler measurements — time-based protocols commonly sample at intervals after injection; Flores uses a rigidity-based assessment. Record timing and hardness, and measure bilaterally at a standardized location. A clock interval alone does not establish maximal response.[1][6]
  4. Doppler parameters recorded:
    • Peak systolic velocity (PSV) at peak systole.
    • End-diastolic velocity (EDV) at end-diastole.
    • Resistive index (RI) = (PSV − EDV) / PSV.
    • Acceleration time — time from onset of systole to peak systole.
    • Cavernosal artery diameter change (pre- and post-injection).
  5. Angle correction — Doppler angle should be ≤ 60° for accurate velocity measurements.[6]
  6. Post-procedure monitoring — confirm detumescence before discharge. A persistent penetration-rigid erection may need intracavernosal phenylephrine under the supervised rescue protocol, with blood pressure and heart-rate monitoring; refractory cases may require aspiration. Distinguish early post-injection prolonged erection from established ischemic priapism, which requires urgent treatment. See the priapism management hub.[1][11]

Sampling Location — A Critical Variable​

The anatomic sampling site can materially change the result. Pagano and Stahl studied 52 men / 104 cavernosal arteries: mean PSV was 52.9 cm/s at the crus, 29.5 proximally and 21.6 at mid-artery. EDV differences were not significant in that cohort; another 210-patient study did find location-related EDV differences.[19][20]

Standardize and document the site, Doppler angle and erection phase. Do not switch to a different sampling location merely to obtain the diagnosis suspected clinically. Apply reference values appropriate to the technique; the historical location studies do not establish interchangeable thresholds.

Interpretation — Normal Values and Diagnostic Criteria​

EAU describes PSV >30 cm/s, EDV <3 cm/s and RI >0.8 as commonly normal. Other specialist protocols use EDV <5 cm/s and different RI thresholds. State the criteria used rather than combine different protocols into one definitive classification.[40][1]

ParameterInterpretation
PSVLow values suggest impaired arterial inflow when stimulation and technique are adequate; borderline values and incomplete relaxation require caution
EDVPersistent positive flow, commonly >5 cm/s in published protocols, may suggest impaired veno-occlusion when arterial inflow and relaxation are adequate
RIDerived from PSV and EDV; an adjunct rather than a stand-alone venous-leak diagnosis
Acceleration / artery diameterSupplementary measurements; neither an isolated timing cutoff nor post-injection diameter establishes arterial disease

A low PSV plus positive EDV during a suboptimal erection does not reliably prove “mixed arterial and venous disease.” Normal hemodynamics do not establish a psychogenic or neurogenic diagnosis; assess the broader history and examination.[4][6][22][23]

Historical cohorts are useful for understanding measurement, not population prevalence. Kaufman's 743-patient DICC series reported 58.9% combined abnormalities in a detailed 124-patient single-center subgroup, not in the entire series.[13] Pathak's 259 men were selected from 2,043 referrals for sustained rigidity and normal Doppler parameters; their age-related PSV association does not define normality for all men.[18]

Diagnostic Accuracy of PDUS for Venous Leak​

Chen's small diagnostic study compared three composite criteria with cavernosography. Deep dorsal flow plus PSV >30 and EDV >5 cm/s had reported sensitivity 91.7%, specificity 70.6% and accuracy 84.9%. Adding RI <0.89 or <0.80 increased specificity but reduced sensitivity and overall accuracy; the study did not evaluate an RI <0.75 add-on.[21] These estimates are study-specific and depend on an imperfect invasive reference standard.

Venous-compression Doppler remains investigational. Gutwein's proof-of-concept study included 40 men, but only 17 underwent compression and only 10 had CT comparison. The reported 90% versus 20% accuracy therefore comes from a small selected comparison. A nonsignificant P value of 0.096 does not establish equivalence to CT cavernosography.[24]

PDUS in Peyronie Disease​

The AUA Peyronie Disease Guideline recommends an in-office ICI test with or without duplex Doppler ultrasound prior to invasive intervention.[8] PDUS provides:[9][25][26]

  • Plaque characterization — location, size, number, and calcification status (calcification may affect treatment feasibility; its extent and the intended therapy matter).
  • Vascular assessment — in Masterson’s 108-man cohort, 48/87 (55%) with questionnaire-defined ED and 20/33 (61%) with severe questionnaire scores had normal Doppler parameters. This demonstrates discordance; it does not prove a psychological or mechanical cause in each patient.[27]
  • Fibrosis — intracavernosal fibrosis was associated with difficulty maintaining erection in the cited cohort; do not extend that result to every fibrotic finding or infer causation.[26]
  • Surgical planning — helps determine whether plication, grafting, or penile prosthesis is most appropriate.[25]

PDUS in Priapism​

Color Doppler ultrasound is invaluable for differentiating priapism subtypes when clinical assessment and blood gas analysis are equivocal:[11][12][28]

  • Ischemic priapism — absent or severely diminished cavernosal artery flow; low / absent PSV; no diastolic flow.
  • Non-ischemic priapism — normal to high cavernosal artery velocities; turbulent flow at the site of arteriovenous fistula; color aliasing.
  • Fistula localization — PDUS identifies the location and size of arterio-lacunar fistulae, guiding selective embolization planning.[11]

The AUA / SMSNA Priapism Guideline recommends PDUS for assessment of fistula location and size in non-ischemic priapism, and notes it can be performed non-urgently.[11]

The STIFF protocol (Sonography to Identify Forward Flow) was described in a single case report using glans compression during Doppler. It has not been validated to predict response or justify withholding phenylephrine; it should not delay established ischemic-priapism treatment.[29]

PDUS in Penile Fracture​

The AUA Urotrauma Guideline states that ultrasound may be performed in patients with equivocal signs and symptoms of penile fracture (Grade C recommendation).[10] Ultrasound can:[10][30]

  • Identify tunica albuginea disruption (discontinuity of the hyperechoic tunica).
  • Differentiate intracavernosal from extracavernosal hematomas.

Routine ultrasound is not necessary when the diagnosis is clinically clear; MRI is an alternative when US is equivocal or unavailable.[10]

Dynamic Infusion Cavernosometry and Cavernosography (DICC)​

Overview​

DICC measures pressure/flow relationships and can map venous drainage. Its positive predictive value and false-positive rate in potent men remain uncertain; the 2013 SOP explicitly recognizes these limitations.[3][4] However, its use has declined substantially as venous ligation surgery has demonstrated poor long-term outcomes.[4][31]

Technique and reported parameters​

Specialist protocols use separate corporal access for pressure measurement and infusion after pharmacologic relaxation. They record equilibrium pressure, flow-to-maintain (FTM), pressure decay after stopping infusion, and sometimes contrast drainage pathways. Document the infusion pressure, drug regimen, units and image timing.[4][13][17]

The historical Kaufman protocol assessed pressure decay from 150 mmHg over 30 seconds and performed cavernosography at 90 mmHg. Other studies used different target pressures. FTM values obtained at different pressures are not interchangeable. Likewise, mL/second and mL/minute differ sixtyfold.[13][31]

Gao's 147-patient observational protocol used flow expressed in mL/second and pressure-decay criteria. Its treatment-linked severity categories are not a consensus grading system. Do not use these study-specific categories as automatic indications for embolization or prosthesis placement.[3] The small controlled Lowe study found substantial overlap in flow/resistance between potent and impotent men, reinforcing the need to interpret the entire study.[32]

Limitations of DICC[4][31]​

  • Invasive — requires corporal puncture, contrast injection, and fluoroscopy.
  • False positives — incomplete smooth muscle relaxation is the most common cause of false-positive results.[4][33]
  • Cavernosography adds limited value — 46% of men with abnormal FTM values had a normal cavernosogram, undermining the utility of the radiographic component, particularly in low-grade venous leak.[31]
  • Declining clinical relevance — as venous ligation surgery has fallen out of favor due to poor long-term outcomes, the anatomic information from cavernosography is less actionable.[31][34]

Gravity Cavernosometry​

A 1991 comparison in 96 men found comparable diagnostic value for gravity and pump techniques, with practical advantages for gravity infusion. Incomplete relaxation limited both. This historical result does not establish contemporary superiority or a universal safety advantage.[33]

Pudendal Arteriography​

Selective internal pudendal arteriography is the definitive test for arterial anatomy and is reserved for young men with post-traumatic ED being considered for penile revascularization surgery.[13][22] In the multi-institutional DICC study, 169 patients underwent arteriography, and 105 proceeded to arterial bypass surgery.[13] It is not used as a screening tool due to its invasiveness.

Advanced Imaging Modalities​

ModalityRoleAdvantagesLimitations
CT cavernosographyVenous leak mapping; validation of PDUS findings3D anatomic detail; identifies venous drainage patternsRadiation; contrast; invasive
CT angiographyPudendal artery anatomy for embolization planning (NIP)Vascular roadmapRadiation; contrast
MRIPenile fracture (equivocal US); tumor staging; cavernosal necrosis in ischemic priapismSuperior soft-tissue contrast; no radiationCost; availability; limited hemodynamic data
Time-resolved MRAArteriovenous shunting; venous leak localizationTemporal + spatial resolution; 85.2% concordance in a selected 26-man studyRequires contrast + ICI; limited availability
Penile angiographyPre-revascularization arterial mapping; therapeutic embolization (NIP)Gold standard for arterial anatomy; therapeutic capabilityInvasive; radiation; contrast

Sources: [12][13][24][35][36][37]

Doppler is the usual hemodynamic examination; MRI can answer selected structural or oncologic questions. Historical reports of plaque detection do not make MRI a routine Peyronie test.[36]

PDUS as a Cardiovascular Risk Marker​

ED is increasingly recognized as an early manifestation of systemic vascular disease. A 2026 retrospective study of 275 men used PSV <35 cm/s and found an association with estimated QRISK3 risk. It was not independent after adjustment for age and diabetes, discrimination was modest (AUC 0.60), and adding PSV barely changed the clinical model. It does not validate PDUS as a cardiovascular screening test or demonstrate prediction of future events.[38]

Practical Pearls and Pitfalls​

  • Incomplete smooth muscle relaxation can produce false-positive results on both PDUS and DICC. Consider stimulation and supervised redosing when appropriate; respect drug-specific limits and document an indeterminate response.[1][4][33]
  • Anxiety-mediated sympathetic tone can produce falsely low PSV and falsely elevated EDV — a private, comfortable environment is essential.[1]
  • Sampling location matters — the large mean differences reported in one study illustrate the need for a consistent documented site; they are not correction factors to add to an individual result.[20]
  • Asymmetric cavernosal artery flow (significant PSV difference between right and left) suggests unilateral arterial disease.[23]
  • Direct venous visualization is not the same as functional assessment. The cited 1990 study of 13 men could not visualize cavernosal venous leaks; that does not mean every patient with suspected dysfunction requires DICC today.[39]
  • Peyronie patients — questionnaire severity can reflect curvature-related intercourse difficulty as well as erectile function. Interpret discordant Doppler findings individually.[27]

Summary of Diagnostic Algorithm​

  1. Begin with history, examination, symptom assessment and appropriate metabolic/hormonal evaluation.
  2. Add PDUS when a vascular question would change management, including selected post-traumatic ED or Peyronie planning.
  3. Reserve DICC/cavernosography for a specific specialist question. It is not the automatic next step after Doppler, and venous ligation is not recommended as routine ED treatment.
  4. Use pudendal arteriography for selected revascularization candidates; it is not general screening.

Most men do not need an escalating sequence of vascular tests. Discuss treatment according to goals and clinical findings, without requiring an invasive test merely to authorize effective ED care.[7][40]

References​

1. Flores JM, West M, Mulhall JP. "Efficient Use of Penile Doppler Ultrasound for Investigating Men With Erectile Dysfunction." J Sex Med. 2024;21(8):734–739. doi:10.1093/jsxmed/qdae070

2. Kho YY, Lee SHE, Chin K, et al. "US of the Penis: Beyond Erectile Dysfunction." Radiographics. 2024;44(6):e230157. doi:10.1148/rg.230157

3. Gao QQ, Chen JH, Chen Y, Song T, Dai YT. "Dynamic Infusion Cavernosometry and Cavernosography for Classifying Venous Erectile Dysfunction and Its Significance for Individual Treatment." Chin Med J. 2019;132(4):405–410. doi:10.1097/CM9.0000000000000099

4. Glina S, Ghanem H. "SOP: Corpus Cavernosum Assessment (Cavernosography / Cavernosometry)." J Sex Med. 2013;10(1):111–114. doi:10.1111/j.1743-6109.2012.02795.x

5. Meuleman EJ, Bemelmans BL, van Asten WN, et al. "Assessment of Penile Blood Flow by Duplex Ultrasonography in 44 Men With Normal Erectile Potency in Different Phases of Erection." J Urol. 1992;147(1):51–56. doi:10.1016/s0022-5347(17)37131-8

6. Varela CG, Yeguas LAM, Rodríguez IC, Vila MDD. "Penile Doppler Ultrasound for Erectile Dysfunction: Technique and Interpretation." AJR Am J Roentgenol. 2020;214(5):1112–1121. doi:10.2214/AJR.19.22141

7. Burnett AL, Nehra A, Breau RH, et al. "Erectile Dysfunction: AUA Guideline." J Urol. 2018;200(3):633–641. doi:10.1016/j.juro.2018.05.004

8. Nehra A, Alterowitz R, Culkin DJ, et al. "Peyronie's Disease: AUA Guideline." J Urol. 2015;194(3):745–753. doi:10.1016/j.juro.2015.05.098

9. McCauley JF, Dean RC. "Diagnostic Utility of Penile Ultrasound in Peyronie's Disease." World J Urol. 2020;38(2):263–268. doi:10.1007/s00345-019-02928-y

10. Morey AF, Broghammer JA, Hollowell CMP, McKibben MJ, Souter L. "Urotrauma Guideline 2020: AUA Guideline." J Urol. 2021;205(1):30–35. doi:10.1097/JU.0000000000001408

11. Bivalacqua TJ, Allen BK, Brock GB, et al. "The Diagnosis and Management of Recurrent Ischemic Priapism, Priapism in Sickle Cell Patients, and Non-Ischemic Priapism: An AUA / SMSNA Guideline." J Urol. 2022;208(1):43–52. doi:10.1097/JU.0000000000002767

12. von Stempel C, Walkden M, Kirkham A. "Review of the Role of Imaging in the Diagnosis of Priapism." Int J Impot Res. 2024. doi:10.1038/s41443-024-00928-0

13. Kaufman JM, Borges FD, Fitch WP, et al. "Evaluation of Erectile Dysfunction by Dynamic Infusion Cavernosometry and Cavernosography (DICC). Multi-Institutional Study." Urology. 1993;41(5):445–451. doi:10.1016/0090-4295(93)90505-5

14. Pfizer. Caverject (alprostadil) prescribing information. Sections 1.2, 2.2 and 5.

15. Meuleman EJ, Bemelmans BL, Doesburg WH, et al. "Penile Pharmacological Duplex Ultrasonography: A Dose-Effect Study Comparing Papaverine, Papaverine/Phentolamine and Prostaglandin E1." J Urol. 1992;148(1):63–66. doi:10.1016/s0022-5347(17)36511-4

16. Bassiem MA, Ismail IY, Salem TA, El-Sakka AI. "Effect of Intracavernosal Injection of Prostaglandin E1 on Duration and Rigidity of Erection in Patients With Vasculogenic Erectile Dysfunction: Is It Dose Dependent?" Urology. 2021;148:173–178. doi:10.1016/j.urology.2020.09.030

17. Bookstein JJ, Valji K, Parsons L, Kessler W. "Penile Pharmacocavernosography and Cavernosometry in the Evaluation of Impotence." J Urol. 1987;137(4):772–776. doi:10.1016/s0022-5347(17)44208-x

18. Pathak RA, Broderick GA. "Color Doppler Duplex Ultrasound Parameters in Men Without Organic Erectile Dysfunction." Urology. 2020;135:66–70. doi:10.1016/j.urology.2019.09.002

19. Pezzoni F, Scroppo FI, Cavallini G. "Differences in Cavernosal Artery Parameters According to Different Anatomic Sampling Locations During the Diagnosis of Vascular Erectile Dysfunction Using Duplex Ultrasound." Urology. 2017;105:33–41. doi:10.1016/j.urology.2017.01.057

20. Pagano MJ, Stahl PJ. "Variation in Penile Hemodynamics by Anatomic Location of Cavernosal Artery Imaging in Penile Duplex Doppler Ultrasound." J Sex Med. 2015;12(9):1911–1919. doi:10.1111/jsm.12958

21. Chen L, Xu L, Wang J, et al. "Diagnostic Accuracy of Different Criteria of Pharmaco-Penile Duplex Sonography for Venous Erectile Dysfunction." J Ultrasound Med. 2019;38(10):2739–2748. doi:10.1002/jum.14982

22. Valji K, Bookstein JJ. "Diagnosis of Arteriogenic Impotence: Efficacy of Duplex Sonography as a Screening Tool." AJR Am J Roentgenol. 1993;160(1):65–69. doi:10.2214/ajr.160.1.8416650

23. Benson CB, Vickers MA. "Sexual Impotence Caused by Vascular Disease: Diagnosis With Duplex Sonography." AJR Am J Roentgenol. 1989;153(6):1149–1153. doi:10.2214/ajr.153.6.1149

24. Gutwein A, Braun AJ, Thalhammer C, et al. "Evaluating the Feasibility of a New Non-Invasive Technique for Improved Diagnostics in Vascular Erectile Dysfunction Using an Ultra-High-Resolution Ultrasound Probe and Venous Compression: A Proof of Concept Study." J Sex Med. 2025;22(6):1024–1034. doi:10.1093/jsxmed/qdaf073

25. Pradeep A, Alexander LF, Padilla-Maldonado GW, et al. "Imaging Techniques for Diagnosing and Managing Peyronie Disease." Abdom Radiol. 2025;50(1):349–359. doi:10.1007/s00261-024-04521-3

26. Chung E, Yan H, De Young L, Brock GB. "Penile Doppler Sonographic and Clinical Characteristics in Peyronie's Disease and/or Erectile Dysfunction: An Analysis of 1500 Men With Male Sexual Dysfunction." BJU Int. 2012;110(8):1201–1205. doi:10.1111/j.1464-410X.2011.10851.x

27. Masterson TA, Efimenko IV, Nackeeran S, Parmar M, Ramasamy R. "Discordant Erectile Function Assessment Between Validated Questionnaire Scores and Penile Doppler Ultrasound in Peyronie's Disease." Int J Impot Res. 2022;34(5):452–455. doi:10.1038/s41443-021-00416-9

28. Pang KH, Alnajjar HM, Lal A, Muneer A. "An Update on Mechanisms and Treatment Options for Priapism." Nat Rev Urol. 2025. doi:10.1038/s41585-025-01069-9

29. Leamon A, Montoya K, Shokoohi H. "A Novel Approach to Priapism Doppler Assessment: Sonography to Identify Forward Flow (STIFF Protocol)." J Emerg Med. 2025;78:33–36. doi:10.1016/j.jemermed.2025.07.051

30. Bertelli E, D'Amico G, Bertolotto M, Miele V. "Penile Ultrasound: An Essential Tool in an Emergency Setting (Traumatic and Non-Traumatic Diseases)." Ultraschall Med. 2022;43(3):232–251. doi:10.1055/a-1748-3995

31. Mulhall JP, Anderson M, Parker M. "Congruence Between Veno-Occlusive Parameters During Dynamic Infusion Cavernosometry: Assessing the Need for Cavernosography." Int J Impot Res. 2004;16(2):146–149. doi:10.1038/sj.ijir.3901177

32. Lowe MA, Schwartz AN, Berger RE. "Controlled Trial of Infusion Cavernosometry in Impotent and Potent Men." J Urol. 1991;146(3):783–785. doi:10.1016/s0022-5347(17)37920-x

33. Meuleman EJ, Wijkstra H, Doesburg WH, Debruyne FM. "Comparison of the Diagnostic Value of Pump and Gravity Cavernosometry in the Evaluation of the Cavernous Veno-Occlusive Mechanism." J Urol. 1991;146(5):1266–1270. doi:10.1016/s0022-5347(17)38065-5

34. Bertolotto M, Campo I, Sachs C, et al. "Sonography of the Penis / Erectile Dysfunction." Abdom Radiol. 2020;45(7):1973–1989. doi:10.1007/s00261-020-02529-z

35. Roudenko A, Wilcox Vanden Berg RN, Song C, et al. "Utility of Dynamic MRA in the Evaluation of Male Erectile Dysfunction." Abdom Radiol. 2020;45(7):1990–2000. doi:10.1007/s00261-019-02339-y

36. Shenoy-Bhangle A, Perez-Johnston R, Singh A. "Penile Imaging." Radiol Clin North Am. 2012;50(6):1167–1181. doi:10.1016/j.rcl.2012.08.009

37. Parker RA, Menias CO, Quazi R, et al. "MR Imaging of the Penis and Scrotum." Radiographics. 2015;35(4):1033–1050. doi:10.1148/rg.2015140161

38. Graziani A, Delbarba A, Nardin M, et al. "Association Between Parameters of Penile Doppler Ultrasound and Cardiovascular Risk in Patients With Erectile Dysfunction: A Single-Center Retrospective Study." J Clin Med. 2026;15(7):2722. doi:10.3390/jcm15072722

39. Vickers MA, Benson CB, Richie JP. "High Resolution Ultrasonography and Pulsed Wave Doppler for Detection of Corporovenous Incompetence in Erectile Dysfunction." J Urol. 1990;143(6):1125–1127. doi:10.1016/s0022-5347(17)40202-3

40. European Association of Urology. Management of erectile dysfunction. Sexual and Reproductive Health Guidelines. 2026. Advanced diagnostic work-up.